Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 79 across all filing types
Latest filing 2026-04-15 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Exchange Next Day Disclosure Return (Form FF305) reporting detailed changes in issued shares and treasury shares, specifically a share repurchase transaction (on-market buyback) with dates, prices, and volumes. This falls under company transactions in its own shares rather than an announcement of a broader financial report or AGM materials. Therefore, it is best classified as Transaction in Own Shares (code POS).
2026-04-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Stock Exchange FF305 "Next Day Disclosure Return" detailing changes in issued shares and treasury shares, specifically reporting the company’s on‐market repurchase of its own shares (quantity, price, mandate, etc.). This is a regulatory disclosure of a share buyback/transaction in own shares, matching the category for share repurchases (Transaction in Own Shares).
2026-04-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) under HKEX listing rules, detailing changes in issued shares and treasury shares and reporting on-market share repurchases (2,400 shares repurchased on 10 April 2026) including price, mandate details and balances. This is not an AGM, earnings release, or proxy statement but a regulatory report of share buyback activity. It therefore falls under “Transaction in Own Shares” (POS).
2026-04-10 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is Hong Kong Stock Exchange Form FF305 “Next Day Disclosure Return” showing detailed share repurchase and treasury share transactions under Main Board Rule 10.06 and related rules. It provides specifics on number of shares repurchased, prices, and confirmations related to the issuer’s own share transactions. This matches the “Transaction in Own Shares” category for share buybacks (POS).
2026-04-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and treasury share transactions. The content includes detailed tables of share repurchase activity, prices, and confirmations of compliance with listing rules. This type of document is a regulatory disclosure about share transactions rather than a financial report or earnings release. It fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length and detail confirm it is not a brief announcement but a formal disclosure report. Therefore, the correct classification is POS with high confidence.
2026-04-08 English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF DRUG MARKETING AUTHORISATION APPLICATION FOR VONOPRAZAN FUMARATE AND SODIUM CHLORIDE INJECTION
Regulatory Filings Classification · 75% confidence The document is a voluntary announcement by Sunshine Lake Pharma regarding the acceptance of its drug marketing authorisation application by China’s National Medical Products Administration. It contains no financial results, no meeting materials, no share or board changes, and is not reporting or publishing a full report. It is a general regulatory/business update announcement, fitting the fallback category of Regulatory Filings (RNS).
2026-04-08 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.